Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas
  
Genetech
An FDA complete response has stalled Genentech's effort to expand Columvi's label
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business